US IPO Pipeline SEC S-1 Filings — June 18, 2026

18-06-2026

Katapult Holdings, Inc. filed an S-4 registration statement on June 18, 2026, related to a business combination. The filing includes extensive financial data for Series A and Series B convertible preferred stock, warrants, debt facilities, and equity compensation plans, covering periods through March 31, 2026. The company has significant outstanding debt, including a senior secured term loan facility and revolving credit facilities, with fair value measurements for derivatives and warrants.

• · The filing includes fair value hierarchy disclosures for warrants and convertible preferred derivatives, with Level 3 inputs used for the New Term Loan Derivative and Convertible Preferred Derivative.
• · The company has a New Revolving Facility and a Senior Secured Term Loan Facility, with minimum and maximum borrowing rates disclosed.
• · Shareholder litigation is noted as a contingent liability as of December 31, 2024 and 2025.
• · The filing covers multiple tax jurisdictions including TX, PA, NH, NC, MA, IL, CA, and other US jurisdictions for fiscal years 2024 and 2025.
• · Employee stock options and restricted stock units are outstanding under the 2014 and 2021 equity plans.

18-06-2026

OZOP ENERGY SOLUTIONS, INC. filed an S-1 registration statement on June 18, 2026, covering financial data through March 31, 2026. The company reported revenue of $1,500,000 for Q1 2026, a significant increase from $500,000 in Q1 2025, driven by growth in sourced and distributed products. However, the company continues to report substantial net losses, with a net loss of $2,000,000 for Q1 2026 compared to a net loss of $1,800,000 in Q1 2025, indicating widening losses despite revenue growth.

• · The S-1 filing includes financial data for the three months ended March 31, 2026, and the years ended December 31, 2025 and 2024.
• · Customer concentration is high: Customer A, B, and C accounted for significant portions of revenue and accounts receivable in Q1 2026 and FY2025.
• · The company has multiple series of preferred stock (Series C, D, E) and convertible notes outstanding.
• · Subsequent events include issuance of a promissory note and a convertible promissory note in April 2026.
• · The company has a financing and registration rights agreement with GHS Investments LLC, with common stock issued in 2024 and 2025.

18-06-2026

Bleichroeder Acquisition Corp. III filed an S-1 registration statement for an initial public offering of 30,000,000 units at $10.00 per unit, each consisting of one Class A ordinary share and one-fourth of one redeemable warrant, aiming to raise $300,000,000. The company is a blank check entity focused on North American and European disruptive growth sectors, with no business combination target selected yet. The offering includes a private placement of 8,500,000 warrants at $1.00 per warrant to the sponsor and CCM, and the sponsor holds 11,500,000 Class B ordinary shares purchased for $25,000, which will convert to Class A shares at a 25% ratio, potentially causing material dilution to public shareholders.

• · The company has not selected any business combination target and has not initiated any substantive discussions.
• · The sponsor purchased 11,500,000 Class B ordinary shares for $25,000, which will convert to Class A at a 25% ratio, potentially causing material dilution.
• · Public shareholders may experience dilution from the exercise of 8,500,000 private placement warrants and conversion of working capital loans.
• · The warrants become exercisable 30 days after the initial business combination and expire five years after.
• · The offering includes a 45-day over-allotment option for up to 4,500,000 additional units.

18-06-2026

Standard Nuclear, Inc. filed an S-1 registration statement with the SEC on June 18, 2026, for an initial public offering of Class A common stock to be listed on the NYSE under the symbol 'STDN'. The offering size and price range are not yet specified, but the company will be a 'controlled company' post-IPO, with founder Thomas Hendrix holding significant voting power through Class B shares (20 votes per share). The company is an emerging growth company and has not yet reported any financial results in this preliminary filing.

• · The initial public offering price per share is estimated to be between $ and $ (range not yet disclosed).
• · The underwriters have been granted an option to purchase up to an additional shares of Class A common stock to cover over-allotments.
• · Up to % of the shares in the offering have been reserved for sale to directors, officers, and certain employees through a reserved share program.
• · The company has two classes of common stock: Class A (1 vote per share) and Class B (20 votes per share, convertible to Class A).
• · Upon completion of the offering, Thomas Hendrix will beneficially own approximately % of the voting power (or approximately % if the over-allotment is exercised in full).
• · The company will be a 'controlled company' under NYSE corporate governance standards.
• · The company has elected to be an 'emerging growth company' and will use reduced public company reporting requirements.
• · The filing references key performance indicators including Total Contract Backlog, Fuel/TRISO Production Capacity, and Regulatory Milestones.
• · The company commissioned a market report from Wood Mackenzie titled 'U.S. Demand for TRISO Fuel' dated March 5, 2026.
• · The S-1 references a 'Class B Conversion' whereby all Class B shares not beneficially owned by Mr. Hendrix will convert to Class A shares immediately prior to the completion of the offering.

18-06-2026

Goodvision AI Inc. filed an S-4 registration statement for a business combination with Goodvision Inc. The filing includes financial data for periods up to March 31, 2026, showing revenue growth but also net losses. The company completed an IPO on October 23, 2025, and has related party transactions with GV Assets Holdings Limited and Waterdrip Investment Ltd.

• · IPO completed on October 23, 2025.
• · Related party transactions with GV Assets Holdings Limited and Waterdrip Investment Ltd. in Q1 2026.
• · Founder shares issued to sponsors and EarlyBird Capital Inc. in 2024 and 2025.
• · Subsequent events include a subscription agreement for Class A common shares on April 30, 2026.

18-06-2026

AIM ImmunoTech Inc. filed an S-1 registration statement for a secondary offering of up to 13,077,089 shares of common stock by selling stockholders, including shares underlying PIPE, Pre-Funded, Class J, and placement agent warrants. The company will not receive proceeds from the stock sale, but could receive up to approximately $5.5 million if all Class J and June Offering Placement Agent Warrants are exercised for cash. The company is focused on developing Ampligen for late-stage pancreatic cancer and other indications, with a Phase 3 trial design agreement with Thermo Fisher Scientific, but faces risks including no FDA approval for Ampligen in the U.S. and a history of operating losses.

• · Pancreatic cancer killed more than 100,000 people in the American and European Union markets and more than 450,000 worldwide in 2026 alone.
• · Ampligen is approved for commercial sale in the Argentine Republic for severe Chronic Fatigue Syndrome but not FDA-approved in the U.S.
• · The DURIPANC study is an investigator-initiated, open-label, single-center study expected to enroll up to 25 subjects in Phase 2, with primary objective of clinical benefit rate.
• · Erasmus MC reported no significant toxicity and 'high' quality of life in Ampligen subjects during treatment.
• · The company has orphan drug designations for Ampligen in the U.S. and European Union.
• · AIM has broad-combination therapy patents in the U.S., Japan, and Europe.
• · The company's stock is listed on NYSE American under symbol 'AIM'.